WHO Drug Information Vol. 15, No. 3 & 4, 2001
(2001; 76 pages) Voir le document au format PDF
Table des matières
Afficher le documentWHO Drug Information
Ouvrir ce répertoire et afficher son contenuPersonal Perspectives
Ouvrir ce répertoire et afficher son contenuReports on Individual Drugs
Ouvrir ce répertoire et afficher son contenuQuality Assurance Issues
Ouvrir ce répertoire et afficher son contenuCurrent Topics
Ouvrir ce répertoire et afficher son contenuGeneral Information
Fermer ce répertoireRegulatory and Safety Matters*
Afficher le documentInfliximab and congestive heart failure
Afficher le documentInfliximab: warning of opportunistic infections
Afficher le documentBrimonidine ophthalmic drops: accidental ingestion
Afficher le documentP-Glycoprotein and drug interaction
Afficher le documentNonacog alfa: intensive surveillance
Afficher le documentTenofovir disoproxil fumarate approved for HIV infection
Afficher le documentCiprofloxacin hydrochloride for inhalation anthrax
Afficher le documentDTPa and limb swelling
Afficher le documentNitrofurantoin and peripheral neuropathy
Afficher le documentContinued suspension for tolcapone
Afficher le documentMMR vaccine and idiopathic thrombocytopenic purpura
Afficher le documentNew communications and networking unit at EMEA
Ouvrir ce répertoire et afficher son contenuATC/DDD Classification
Ouvrir ce répertoire et afficher son contenuRegulatory Information
Afficher le documentRecommended International Nonproprietary Names (rec. Inn): List 46
Afficher le documentSelected WHO Publications of Related Interest
 

Nitrofurantoin and peripheral neuropathy

Australia - A recent letter to the Medical Journal of Australia has highlighted a case of peripheral neuropathy in association with nitrofurantoin, an antibiotic used for urinary tract infection prophylaxis (1). This is a well known effect of nitrofurantoin but awareness may be declining due to reduced use.

The Australian Adverse Drug Reactions Committee (ADRAC) has received 18 reports of peripheral neuropathy since 1978. While there were no reports received between 1990 and 1997, there have been three in the last 4 years. Most of the reports have involved elderly females. Daily dosages have ranged from 100 mg to 400 mg with a median of 250 mg. The time to onset has ranged from 3 weeks to over 12 months (median: 2-3 months) before the reaction was identified. Only 4 of the 18 patients were documented as having recovered at the time the report was submitted to ADRAC. Peripheral neuropathy can be both severe and irreversible.

Prescribers should take care with the use of nitrofurantoin in the elderly, those with renal impairment and those taking the drug for prolonged periods. Particular attention to the use of the minimum effective dose may reduce the possibility of occurrence of peripheral neuropathy and any suggestive symptoms should trigger cessation of the drug.

Reference:

1. Australian Adverse Drug Reactions Bulletin, Volume 20; Number 3, 2001.

2. Spring, P.J., Sharpe, D.M., Hayes, M.W. Nitrofurantoin and peripheral neuropathy: a forgotten problem? Medical Journal of Australia, 174: 153-154 (2001).

vers la section précédente vers la section suivante
 

Dernière mise à jour: le 24 avril 2012